证券代码：688108 证券简称：赛诺医疗 公告编号：2025-040 赛诺医疗科学技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、说明会类型 赛诺医疗科学技术股份股份有限公司（以下简称"赛诺医疗"或"公司"） 于 2025 年 08 月 22 日在上海证券交易所网站（http://www.sse.com.cn）上披露 了《赛诺医疗科学技术股份有限公司 2025 年半年度报告》及其摘要。 为加强与投资者的深入交流，便于广大投资者更全面深入地了解公司，在上 海证券交易所的支持下，公司计划于 2025 年 09 月 03 日 16:00-17:00 在上证路 演中心（网址：https://roadshow.sseinfo.com/）以网络文字互动问答的方式 举行赛诺医疗 2025 年半年度业绩说明会，与广大投资者进行充分交流，解答投 资者普遍关注的问题。 二、说明会召开的时间、地点 1、会议召开时间：2025 年 09 月 03 日 16:0 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-039 赛诺医疗科学技术股份有限公司关于 子公司产品获得国内医疗器械注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）控股子公 司赛诺神畅医疗科技有限公司（以下简称"赛诺神畅"）收到国家药品监督管理局（以下 简称"国家药监局"）颁发的《中华人民共和国医疗器械注册证》，现将相关情况公告如 下： 适用范围：该产品用于一般性血管内操作，包括在神经血管内输注诊断性制剂(造 影剂)和适当的器械(弹簧圈、支架)。 有效期至：2030 年 8 月 21 日 二、医疗器械基本情况 本次获得《医疗器械注册证》的一次性使用微导管，是由公司控股子公司赛诺神畅 自主研发并进行生产的一款导管产品。该产品为单腔器械，有半刚性的近端部分和柔韧 的远端部分。微导管手柄上有鲁尔接头可以用来连接附件。微导管远端有不透射线标记， 可以在 X 射线下清晰可辨。微导管外表面涂有亲水涂层，能减少血管 ...

Financial Performance - In the first half of 2025, the company achieved revenue of 240 million (up 12.53% year-on-year), net profit attributable to shareholders of 14 million (up 296.54%), and net profit excluding non-recurring items of 8 million (up 163.35%) [1] - In Q2 2025, the company reported revenue of 140 million (up 13.86%), net profit attributable to shareholders of 11 million (up 110.56%), and net profit excluding non-recurring items of 7 million (up 42.83%) [1] Product Development and Market Expansion - The company is successfully advancing its coronary intervention consumables both domestically and internationally, with steady sales growth in coronary stents and balloons participating in national and provincial procurement [2] - As of August 22, 2025, the second round of volume-based procurement for coronary stents has been executed in most provinces, and the company has completed follow-up procurement for coronary balloons in most regions [2] - The company’s coronary drug-eluting stent system has received overseas registration in countries such as Argentina, Ecuador, and Vietnam, while its coronary balloon products have been registered in Kyrgyzstan, Peru, and Malaysia, expanding its international sales footprint [2] Regulatory Approvals and Innovations - The company received FDA notification for its self-expanding drug-coated intracranial stent system and COMEX balloon microcatheter, which have been granted Breakthrough Device Designation, marking a significant milestone as the first product of its kind for treating intracranial atherosclerosis [3] - The company’s subsidiary has also developed a flow-directed mesh stent that received medical device registration in China and is under CE registration review in Europe [3] Profit Forecast and Investment Rating - Due to increased expenses for new product promotion and R&D, the company has revised its net profit forecasts for 2025-2026 down to 31 million and 58 million respectively, with an expected net profit of 80 million for 2027 [3] - The corresponding PE ratios based on current market capitalization are projected to be 433, 234, and 170 times for the respective years, maintaining a "buy" rating considering the anticipated domestic launch of the intracranial self-expanding drug-coated stent [3]

Group 1 - The stock exchange has implemented monitoring measures for stocks that exhibit significant abnormal fluctuations in trading, particularly focusing on large buy or sell orders within a one-minute timeframe during continuous bidding phases [1] Group 2 - A list of stocks under abnormal fluctuation monitoring has been provided, including their monitoring start and end dates, as well as the dates when the fluctuations began. Notable stocks include 思泉新材, *ST苏吴, 赛诺医疗, 东芯股份, and 长城军工 [2]

Core Viewpoint - Sino Medical reported a significant increase in net profit and revenue for the first half of 2025, despite recent stock price volatility and a notable drop in share price over three consecutive trading days [4][6]. Trading Information Summary - On August 22, 2025, Sino Medical's stock closed at 32.7 yuan, down 4.44%, with a turnover rate of 14.54% and a trading volume of 605,100 shares, amounting to a total transaction value of 2.01 billion yuan [1]. - The capital flow on the same day showed a net outflow of 209 million yuan from main funds, accounting for 10.4% of the total transaction value, while retail investors saw a net inflow of 7.39 million yuan, representing 3.68% of the total [2][7]. Shareholder Changes - As of June 30, 2025, the number of shareholders for Sino Medical was 11,100, an increase of 46 from March 31, 2025, reflecting a growth rate of 0.42% [3][7]. Performance Disclosure Highlights - For the first half of 2025, Sino Medical achieved a main revenue of 240 million yuan, a year-on-year increase of 12.53%, and a net profit attributable to shareholders of 13.84 million yuan, up 296.54% [4][5]. - The second quarter alone saw a main revenue of 140 million yuan, a 13.86% increase year-on-year, and a net profit of 10.87 million yuan, reflecting a 110.56% rise [4]. Company Announcements Summary - Sino Medical's total assets as of the end of the reporting period were approximately 1.31 billion yuan, a 0.70% increase from the previous year, while the net assets attributable to shareholders rose by 3.13% to approximately 894 million yuan [5]. - The company’s R&D expenditure accounted for 32.36% of its revenue, a decrease of 10.80 percentage points compared to the previous year [5].

Investment Rating - The report maintains a "Buy" rating for the company [1][10] Core Insights - The company received FDA breakthrough device designation for its self-expanding drug-coated stent system, marking a significant milestone as the first product of its kind for intracranial atherosclerotic stenosis treatment [3] - The company reported a revenue of 240 million yuan in the first half of 2025, reflecting a year-on-year growth of 12.53%, and a net profit attributable to shareholders of 14 million yuan, up 296.54% year-on-year [9] - The company is actively expanding its coronary intervention consumables both domestically and internationally, with successful participation in various procurement projects [9] Financial Projections - The total revenue is projected to reach 573.42 million yuan in 2025, with a year-on-year growth of 25% [1] - The net profit attributable to shareholders is expected to be 31.41 million yuan in 2025, showing a significant increase of 1,997.13% compared to the previous year [1] - The earnings per share (EPS) is forecasted to be 0.08 yuan in 2025, with a price-to-earnings (P/E) ratio of 433.13 based on the current market price [1][10]

Core Viewpoint - Sino Medical (688108) experienced significant stock price fluctuations, with a recent decline of 5.41% and a peak price of 47.0 yuan, indicating volatility in the market [1][2]. Trading Information Summary - Sino Medical's stock was listed on the "Dragon and Tiger List" twice this week due to price deviation limits being reached, marking the second and third occurrences in five trading days [2][6]. Shareholder Changes - As of June 30, 2025, the number of shareholders for Sino Medical increased to 11,100, reflecting a growth of 46 shareholders or 0.42% since March 31, 2025. The average shareholding per account rose slightly to 37,500 shares, with an average market value of 420,900 yuan [3]. Performance Disclosure Highlights - For the first half of 2025, Sino Medical reported a main revenue of 240 million yuan, a year-on-year increase of 12.53%. The net profit attributable to shareholders reached 13.84 million yuan, up 296.54%, while the non-recurring net profit was 7.98 million yuan, increasing by 163.35%. In Q2 2025, the company achieved a revenue of 140 million yuan, a 13.86% year-on-year growth, with a net profit of 10.87 million yuan, reflecting a 110.56% increase [4][6]. Company Announcement Summary - Sino Medical's subsidiary received FDA breakthrough device designation for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, although this does not guarantee future approval for market entry. The company's blood flow-directed mesh stent products have been listed and won bids in several provinces, but sales and implantation forecasts remain uncertain. The projected net profits for 2023 and 2024 are -39.63 million yuan and 1.50 million yuan, respectively, with an expected net profit of 13.84 million yuan for the first half of 2025 [5][6].

Group 1 - The core stock price of Sino Medical (688108) closed at 32.7 yuan on August 22, 2025, down 4.44% with a turnover rate of 14.54% and a trading volume of 605,100 hands, resulting in a transaction amount of 2.01 billion yuan [1] - On August 22, 2025, the net outflow of main funds was 209 million yuan, accounting for 10.4% of the total transaction amount, while retail investors saw a net inflow of 7.39 million yuan, representing 3.68% of the total transaction amount [1] - The financing data on August 22, 2025, showed a financing buy of 316 million yuan and a financing repayment of 329 million yuan, resulting in a net repayment of 12.7 million yuan [2][3] Group 2 - Sino Medical's total market value is 13.605 billion yuan, with a net asset of 925 million yuan and a net profit of 13.8416 million yuan, ranking 25th, 105th, and 79th respectively in the medical device industry [5] - The company's revenue for the first half of 2025 was 240 million yuan, a year-on-year increase of 12.53%, while the net profit attributable to shareholders was 13.8416 million yuan, up 296.54% year-on-year [5] - The gross profit margin of Sino Medical is 63.64%, which is higher than the industry average of 51.3%, while the net profit margin is 5.48%, lower than the industry average of 11.01% [5]

来源：金融界 最近三个交易日，20日-22日，赛诺医疗分别获融资买入3.78亿元、3.31亿元、3.16亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 8月22日，沪深两融数据显示，赛诺医疗获融资买入额3.16亿元，居两市第70位，当日融资偿还额3.29亿 元，净卖出1269.64万元。 ...

Core Viewpoint - The article highlights that Sino Medical has shown significant financial recovery and potential for growth, particularly with its drug-eluting stent receiving FDA conditional approval, marking a pivotal moment for domestic medical devices in the U.S. market [2][33]. Financial Performance - Revenue has recovered to 240 million yuan, an increase of 12.53% year-on-year [5]. - Net profit reached 13.84 million yuan, a year-on-year increase of 296.54% [5]. - The operating cash flow net amount was 52.45 million yuan, up 303.38% year-on-year, exceeding net profit [11]. - Gross margin remained stable at 71%, indicating that price pressures have been absorbed by structural and cost adjustments [11]. Business Progress - The coronary intervention business generated 187 million yuan, a growth of 17.40%, accounting for 78% of total revenue [6]. - The company has expanded its international market presence, with products approved in countries like Argentina and Ecuador [14]. - The FDA conditional approval for the new drug-eluting stent system is a significant milestone, potentially opening the U.S. market for Sino Medical [14]. R&D and Innovation - R&D expenses were 77.8 million yuan, accounting for 32.36% of revenue, which is significantly higher than the industry average [21]. - The company has a robust pipeline covering three major high-barrier areas: coronary, neuro, and structural heart disease [22]. - The introduction of AI in production processes aims to enhance product consistency and stability, crucial for future overseas supply [22]. Market Position and Strategy - Sino Medical is positioned as a resilient player in a challenging environment, focusing on both immediate recovery and long-term growth through innovation [10][20]. - The company is not solely reliant on one business line but is diversifying its offerings to navigate competitive pressures [17]. - The potential for FDA approval and successful market penetration in the U.S. could redefine Sino Medical's industry standing [27][32].